BerGenBio

Board/Management Information • Mar 13, 2019

BerGenBio ASA ("BerGenBio" or "the Company") announces key appointments to executive team and Board to prepare organisation for next phase of development

BerGenBio ASA ("BerGenBio" or "the Company") announces key appointments to executive team and Board to prepare organisation for next phase of development

Bergen, Norway, 14 March 2019 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing a pipeline of first-in-class AXL kinase

inhibitors to treat multiple cancer indications, announces today changes made to

its executive team and Board of Directors, to strengthen the organisation and

prepare it for late stage clinical trials towards the second half of 2019.

(i) Executive team

Specifically, Dr Dominic Smethurst (MA MBChB MRCP MFPM) has been appointed Chief

Medical Officer (CMO) in a permanent capacity taking over from Interim CMO Dr

Alan Barge. Dominic trained as a physician in Cambridge and Nottingham and

brings two decades of experience in clinical development and leadership roles

within the biopharma industry and leading consultancies including AstraZeneca,

Amgen, Prescient Life Sciences and ICON.

Most recently, he served as CMO at Tusk Therapeutics Ltd, an immune-oncology

biotech which was acquired by Roche in 2018.

Further, the Company has made key hires strengthening its regulatory affairs

function and announces that Dr Anthony Brown will be leaving his post as Chief

Scientific Officer (CSO) to pursue other opportunities.

(ii) Changes to the Board

Following the Company's Annual General Meeting (AGM) held on 13 March 2019 the

following Board changes have become effective:

· Grunde Eriksen,

· Dr Debra Barker, and

· Dr Pamela A. Trail

have joined the Board as Non-Executive Directors.

Grunde Eriksen is the founder and CEO of Altitude Capital AS, a private

investment company established in 2016. Grunde is an experienced capital markets

advisor and investor. He began his career in 1998 in Stockholms Enskilda Bank's

("SEB") corporate finance division in Stockholm before moving to the equity

capital markets team in London. He then spent a further two years at SEB in

Norway before joining Arctic Securities in 2007 as a partner working in equity

sales. He is a Norwegian citizen.

Dr Debra Barker is a seasoned clinical development executive with experience

from Novartis, Roche, Smithkline Beecham and Knoll and served until recently as

the Chief Medical and Development Officer at Polyphor Ltd. Dr Barker has a

Diploma in Pharmaceutical Medicine and received a MSc in immunology from the

King's College in London and a Medical Degree from the Queens College,

Cambridge, UK. She is a UK-Swiss citizen.

Dr Pamela A. Trail is CSO of Molecular Partners AG. Previously she held key

strategic oncology leadership roles at Regeneron, MedImmune, Bayer Healthcare

and BMS and served as CSO at Seattle Genetics. Dr. Trail received her Ph.D. from

the University of Connecticut, Storrs, CT and was a postdoctoral Research Fellow

at the Memorial Sloan-Kettering Institute for Cancer Research, NY.

Stein Holst Annexstad, Hilde Furberg, Kari Grønås, and Jon Øyvind Eriksen have

resigned from the Board. Sveinung Hole, previously a Non-Executive Director, has

become Chair, and Stener Kvinnsland remains as a Non-Executive Director.

Sveinung Hole, Chair at BerGenBio, commented: «We welcome Grunde, Debra and

Pamela to the Board. All three are highly experienced in their respective fields

and will add significant strength and depth to our Board at this exciting time

for BerGenBio as we push towards key value-driving catalysts this year and

beyond. Their insight and knowledge will be invaluable as we focus on initiating

late stage clinical trials with bemcentinib in acute myeloid leukaemia and non

-small cell lung cancer, as well as initiating a first-in-patient phase 1b trial

for our BGB149 antibody.

«I would also like to thank Stein, Hilde, Kari and Jon for their valuable

contribution to BerGenBio's progress during their time on the Board, we wish

them well in their future endeavours.»

-End-

For more information, please contact

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

+47 917 86 513

Media relations

Crux Advisers

Jan Petter Stiff

stiff@crux.no

+47 995 13 891

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Jessica Hodgson, Nicholas Brown

bergenbio@consilium-comms.com

+44 20 3709 5700

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.